Article PDF
Avoid common mistakes on your manuscript.
References
RCPCH. Guidance — Paediatric multisystem inflammatory syndrome temporally associated with COVID-19.Available from: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19. Accessed May 02, 2020.
Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. Coronavirus Disease (COVID-19) in Children — What We Know So Far and What We Do Not?. Indian Pediatr.2020 Apr 9 [Epub ahead of print]. Available from:https://www.indianpediatrics.net/COVID29.03.2020/SA-00159.pdf. Accessed May 09, 2020.
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020 May 07. [Epub ahead of print]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31094-1/fulltext. Accessed on May 09, 2020.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020 Apr 10. [Epub ahead of print]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194613/pdf/main.pdf. Accessed May 09, 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
ClinicalTrials.gov: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04320615. Accessed May 03, 2020.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID 19: A single center experience. J Med Virol. 2020 Apr 06 [Epub ahead of print]. Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25801. Accessed May 9, 2020.
Funding
Funding: None
Author information
Authors and Affiliations
Contributions
Contributors: SB,TMN,BR: took part in treating the patient and preparing the manuscript; AVR: patient management and preparing the manuscript.
Corresponding author
Ethics declarations
Competing interest: None stated.
Rights and permissions
About this article
Cite this article
Balasubramanian, S., Nagendran, T.M., Ramachandran, B. et al. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab. Indian Pediatr 57, 681–683 (2020). https://doi.org/10.1007/s13312-020-1901-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-020-1901-z